HHCP
TYRA icon

Hilton Head Capital Partners’s Tyra Biosciences TYRA Stock Holding History

Hilton Head Capital Partners’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.6K Buy
2,024
+1,252
+162% +$41.4K 0.03% 284
2026
Q1 		$29.6K Buy
+772
New +$25K 0.02% 394

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Hilton Head Capital Partners's TYRA Position: Q2 2026 in Review

Hilton Head Capital Partners increased its Tyra Biosciences (TYRA) stake by 162% in Q2 2026, buying an estimated $41.4K and bringing the position to 2,024 shares worth $64.6K. The position accounts for 0.03% of the portfolio, ranked #284.

Hilton Head Capital Partners first reported a position in TYRA in Q1 2026 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Hilton Head Capital Partners held 2,024 shares of Tyra Biosciences worth $64.6K as of Q2 2026.
  • Hilton Head Capital Partners bought 1,252 Tyra Biosciences shares in Q2 2026, an estimated $41.4K.
  • Tyra Biosciences made up 0.03% of Hilton Head Capital Partners's portfolio in Q2 2026, its #284 holding.
  • Hilton Head Capital Partners first reported a position in Tyra Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.